Kindred Biosciences (KIN) Reports In-Line Q1 EPS, Revenues Miss
Get Alerts KIN Hot Sheet
Join SI Premium – FREE
Kindred Biosciences (NASDAQ: KIN) reported Q1 EPS of ($0.24), in-line with the analyst estimate of ($0.24). Revenue for the quarter came in at $2.4 million versus the consensus estimate of $3.45 million.
"We had a strong start to the year, announcing positive results in a new long-acting interleukin-31 antibody program that has the potential to become a best-in-class therapeutic, alongside the acceptance of efficacy data for our parvovirus monoclonal antibody program. With cash runway now through the end of 2023, we are well-positioned to realize the value of our promising late-stage pipeline," said KindredBio's Chief Executive Officer, Richard Chin, M.D.
For earnings history and earnings-related data on Kindred Biosciences (KIN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Safe & Green (SGBX) Provides Update on Audit and Planned 10-K Filing
- Parke Bancorp (PKBK) Reports Q1 EPS of $0.51
- Schlumberger (SLB) earnings in-line, revenue beats expectations
Create E-mail Alert Related Categories
Corporate News, Earnings, Management CommentsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!